Healthy Japanese
Conditions
Interventions
<
Duration>
Test 1: Active capsule and placebo drink Test 2: Active drink and placebo capsule *The intervention sequence is test 1 to test 2. *Washout period is one week or more.
<
Test 1: Active drink and placebo capsule Test 2: Active capsule and placebo drink *The intervention sequence is test 1 to test 2. *Washout period is one week or more.
Sponsors
ORTHOMEDICO Inc.
Medical Corporation Seishinkai, Takara Clinic Nerima Medical Association, Minami-machi Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Japanese 2. Men or women 3. Adults 4. Healthy individuals 5. Individuals whose body mass index (BMI) is 18.5 kg/m2 or more and less than 25 kg/m2
Exclusion criteria
Exclusion criteria: 1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction 2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims" 5. Individuals who are taking or using medications (including herbal medicines) and supplements 6. Individuals who are allergic to medicines or foods related to test products 7. Individuals who are pregnant, lactating, or planning to become pregnant during this study 8. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study 9. Individuals who do not have any pre-existing diseases of the digestive organ (irritable bowel syndrome, inflammatory bowel disease, gastric ulcer, reflux esophagitis) 10. Individuals who are judged as ineligible to participate in this study by the physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The change of concentration of astaxanthin compounds in the blood 2. Pharmacokinetics parameter | — |
Countries
Japan
Contacts
Public ContactNaoko Suzuki
ORTHOMEDICO Inc. R&D Department
Outcome results
None listed